Related references
Note: Only part of the references are listed.α-Galactosidase A/lysoGb3 ratio as a potential marker for Fabry disease in females
G. Baydakova et al.
CLINICA CHIMICA ACTA (2020)
The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts
Dominique P. Germain et al.
MOLECULAR GENETICS AND METABOLISM (2019)
Migalastat: A Review in Fabry Disease
Emma H. McCafferty et al.
DRUGS (2019)
Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study
Christoffer V. Madsen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment
Puriya Daniel Yazdanfard et al.
PLOS ONE (2019)
Analysis of globotriaosylceramide (Gb3) isoforms/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography/tandem mass spectrometry
Amanda Toupin et al.
ANALYTICA CHIMICA ACTA (2018)
Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease
Albina Nowak et al.
MOLECULAR GENETICS AND METABOLISM (2018)
Major Organic Involvement in Women with Fabry Disease in Argentina
Fernando Perretta et al.
TheScientificWorldJOURNAL (2018)
Major Organic Involvement in Women with Fabry Disease in Argentina
Fernando Perretta et al.
Scientific World Journal (2018)
Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy
Hitoshi Sakuraba et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2018)
Fabry Disease in Families With Hypertrophic Cardiomyopathy Clinical Manifestations in the Classic and Later-Onset Phenotypes
Berglind Adalsteinsdottir et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2017)
Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients
Michel Boutin et al.
ANALYTICAL CHEMISTRY (2017)
Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation
Christiane Auray-Blais et al.
CLINICA CHIMICA ACTA (2017)
Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
Malte Lenders et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry
Christiane Auray-Blais et al.
CLINICA CHIMICA ACTA (2015)
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
Marieke Biegstraaten et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Positron Emission Tomography and Magnetic Resonance Imaging of the Brain in Fabry Disease: A Nationwide, Long-Time, Prospective Follow-Up
Kirsten Korsholm et al.
PLOS ONE (2015)
Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement
Hans C. Fledelius et al.
ACTA OPHTHALMOLOGICA (2015)
Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α
Kazuya Tsuboi et al.
GENETICS IN MEDICINE (2014)
Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance
B. E. Smid et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa
Hsiang-Yu Lin Abcde et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2014)
Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease
Thaneas Prabakaran et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Risk of Death in Heart Disease is Associated With Elevated Urinary Globotriaosylceramide
Raphael Schiffmann et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Multiplex Analysis of Novel Urinary Lyso-Gb3-Related Biomarkers for Fabry Disease by Tandem Mass Spectrometry
Pamela Lavoie et al.
ANALYTICAL CHEMISTRY (2013)
Fabry disease in children: agalsidase-beta enzyme replacement therapy
L. Borgwardt et al.
CLINICAL GENETICS (2013)
A Metabolomic Study Reveals Novel Plasma Lyso-Gb3 Analogs As Fabry Disease Biomarkers
F. O. Dupont et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Urinary Globotriaosylsphingosine-Related Biomarkers for Fabry Disease Targeted by Metabolomics
Christiane Auray-Blais et al.
ANALYTICAL CHEMISTRY (2012)
Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy
Marielle J. van Breemen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
Bouwien E. Smid et al.
ORPHANET JOURNAL OF RARE DISEASES (2011)
Biomarkers of Fabry Disease Nephropathy
Raphael Schiffmann et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Serum Globotriaosylceramide Assay as a Screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea
Jeong-Yup Kim et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2010)
Autonomic skin responses in females with Fabry disease
Anette T. Moller et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2009)
Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease
Christiane Auray-Blais et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
William R. Wilcox et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
Johannes M. Aerts et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Osteopenia:: a common aspect of Fabry disease.: Predictors of bone mineral density
Henriette Mersebach et al.
GENETICS IN MEDICINE (2007)
Narrative review: Fabry disease
Joe T. R. Clarke
ANNALS OF INTERNAL MEDICINE (2007)
The Dutch Fabry cohort:: Diversity of clinical manifestations and Gb3 levels
A. C. Vedder et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2007)
Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life
Raymond Y. Wang et al.
GENETICS IN MEDICINE (2007)
Small-fibre neuropathy in female Fabry patients:: reduced allodynia and skin blood flow after topical capsaicin
Anette T. Moller et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2006)
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting
R Schiffmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Is globotriaosylceramide a useful biomarker in Fabry disease?
E Young et al.
ACTA PAEDIATRICA (2005)
Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease
K Mills et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2005)
Share Paper
